Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC
Prof Yi-Long Wu speaks to ecancer about a phase 2 study of JS207 plus chemotherapy in patients with unresectable stage III NSCLC.
JS207, a bispecific antibody targeting PD-1 and VEGF, combined with platinum-based chemotherapy shows encouraging activity in patients with unresectable stage III NSCLC.
In this phase II study, 22 of 42 patients underwent surgery following neoadjuvant treatment, with a pathological complete response rate of 54.5% and a major pathological response rate of 72.7%.
Prof Wu further covers the safety profile of the combination. He notes that anaemia and reductions in neutrophil and white blood cell counts among the most common adverse events.
Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC
Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in perioperative lung cancer management?
Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC
MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated non-small cell lung cancer
Durvalumab improves survival and delays progression in limited-stage small cell lung cancer
Osimertinib plus local therapy improves outcomes in EGFR-mutant metastatic lung cancer
Pembrolizumab plus chemotherapy delivers lasting benefit in early-stage NSCLC
Becotarug plus osimertinib shows survival benefit in EGFR exon 20 insertion lung cancer
SHR-A2009 plus EGFR tyrosine kinase inhibitor shows promising activity in EGFR-mutant lung cancer